The University of Chicago Header Logo

Connection

John Moroney to Maytansine

Back to Details
This is a "connection" page, showing publications John Moroney has written about Maytansine.
John Moroney
Connection Strength
0.454
Maytansine
  1. Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor a-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr; 26(4):503-515.
    View in: PubMed
    Score: 0.238
  2. Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 12 07; 389(23):2162-2174.
    View in: PubMed
    Score: 0.217
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.